Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
191.75(c) 191.9(c) 193.95(c) 190.85(c) 188(c) Last
257 132 139 779 366 779 570 912 427 381 Volume
+0.97% +0.08% +1.07% -1.60% -1.49% Change
More quotes
Financials
Sales 2020 17 781 M 2 883 M 2 883 M
Net income 2020 1 355 M 220 M 220 M
Net Debt 2020 3 726 M 604 M 604 M
P/E ratio 2020 27,5x
Yield 2020 1,51%
Sales 2021 17 430 M 2 826 M 2 826 M
Net income 2021 1 895 M 307 M 307 M
Net Debt 2021 1 940 M 315 M 315 M
P/E ratio 2021 20,1x
Yield 2021 2,01%
Capitalization 37 358 M 6 043 M 6 057 M
EV / Sales 2020 2,31x
EV / Sales 2021 2,25x
Nbr of Employees 5 761
Free-Float 30,8%
More Financials
Company
H. Lundbeck A/S specializes in the development, production and marketing of medicines for the treatment of psychiatric and neurological disorders (depression, schizophrenia, Lennox-Gastaut syndrome, Parkinson's disease, Huntington's disease, epilepsy, sleep disorders, etc.). 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Notations Surperformance© of H. Lundbeck A/S
Trading Rating : Investor Rating :
More Ratings
All news about H. LUNDBECK A/S
11/30H LUNDBECK A/S : The Danish Business Authority requires Lundbeck to conduct a ne..
AQ
11/27H LUNDBECK A/S : The Danish Business Authority ("Erhvervsstyrelsen") requires Lu..
AQ
11/03H LUNDBECK A/S : Solid performance across strategic brands with 19% growth in th..
AQ
11/03H. LUNDBECK A/S : 3rd quarter results
CO
10/09H LUNDBECK A/S : Lundbeck successfully places its first EUR 500 million Eurobond..
AQ
10/08H LUNDBECK A/S : Lundbeck successfully places its first EUR 500 million Eurobond..
AQ
09/18H LUNDBECK A/S : Lundbeck presents positive data from the COMPLETE study with vo..
AQ
09/17H LUNDBECK A/S : Lundbeck presents positive data from the COMPLETE study with vo..
AQ
09/01H. LUNDBECK A/S : - Positive headline results from the Vyepti RELIEF study
AQ
08/13H LUNDBECK A/S : Strong momentum across all strategic brands with 25% growth in ..
AQ
08/13H. LUNDBECK A/S : Half-year results
CO
08/05H LUNDBECK A/S : Lundbeck discontinues phase II proof of concept study of Lu AF1..
AQ
06/09H LUNDBECK A/S : Lundbeck plans to refocus and reinvigorate Research & Developme..
AQ
06/04Setback for Lundbeck as EU court adviser backs EU antitrust fine
RE
05/13H LUNDBECK A/S : Transactions with shares and linked securities in H. Lundbeck A..
AQ
More news
News in other languages on H. LUNDBECK A/S
04:35pINDEXÄNDERUNG/Siltronic in Stoxx-600 - Cancom ausgeschieden
11/04Coucou, me revoilou ?
11/04AVIS D'ANALYSTES DU JOUR : Adecco, BNP Paribas, Carrefour, Lundbeck, Qiagen, Sch..
09/25TOUR DU MONDE DES INDICES :  Tesla-dépendance et irréductibles danois
08/28Quand les poules auront des dents !
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 226,21 DKK
Last Close Price 188,00 DKK
Spread / Highest target 78,2%
Spread / Average Target 20,3%
Spread / Lowest Target -9,57%
EPS Revisions
Managers
NameTitle
Deborah L. Dunsire President & Chief Executive Officer
Lars Sřren Rasmussen Chairman
Anders Götzsche Chief Financial Officer, Director & Executive VP
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK A/S-24.98%6 087
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389